Regarding the article: Update on the genetic bases and therapeutic perspectives in X-linked Agammaglobulinemia or Bruton´s disease
Keywords:
Agammablobulinemia, Cromosoma X, Enfermedades de Inmunodeficiencia Primaria, Enfermedades del Sistema InmuneAbstract
Regarding the article: Update on the genetic bases and therapeutic perspectives in X-linked Agammaglobulinemia or Bruton´s disease
Downloads
References
1. Hernández-Pacheco JI, Lorenzo-Rodriguez MA. Actualización sobre las bases genéticas y perspectivas terapéuticas en la Agammaglobulinemia ligada al X. Rev Ciencias Médicas [Internet]. 2024 [citado: 20/03/2024]; 28(1): e6271. Disponible en: http://revcmpinar.sld.cu/index.php/publicaciones/article/view/6271
2. El diagnóstico molecular, esencial en el estudio de los errores de la inmunidad innata [Internet]. NIH; 2023 [citado 20/03/2024]. Disponible en: https://healthincode.com/diagnostico-molecular-errores-inmunidad-innata/
3. Sánchez-Artigas R, Díaz-Armas MT, Rodríguez-Duque R, Miguel-Soca PE. Principios y aplicaciones médicas de la edición de genes mediante CRISPR/Cas. Medisur [Internet]. 2021 [citado: 20/03/2024]; 19(6): 1005-14. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttex&pid=S1727-897X2021000601005
4. Liu X, Li G, Liu Y, Zhou F, Huang X, Li K. Avances en la terapia génica CRISPR/Cas para errores congénitos de la inmunidad. Inmunol Front [Internet]. 2023 [citado 20/03/2024]; 14: 1111777 Disponible en: https://europepmc.org/article/med/37051232
5. Gray DH, Villegas I, Long J, Santos J, Keir A, Abele A, et al. Optimizing integration and expression of transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia. CRISPR J [Internet]. 2021 [citado 20/03/2024]; 4(2): 191-206. Disponible en: https://www.liebertpub.com/doi/full/10.1089/crispr.2020.0080
6. GOV. UK. MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent beta-thalassemia [Internet]. GOV. UK; 2023 [citado 20/03/2024] Disponible en: https://www.gov.uk/government/news/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
